首頁 > 市場調查報告書 > 材料/化學品

化學品

市場調查報告書

商品編碼

2068647

醫藥精細化學品市場預測至2034年－按產品類型、合成類型、應用、最終用戶和地區分類的全球分析

Pharmaceutical Fine Chemicals Market Forecasts to 2034 - Global Analysis By Product Type, Synthesis Type, Application, End User, and By Geography

出版日期: 2026年06月11日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，2026 年全球醫藥精細化學品市場規模將達到 1,659 億美元，預計在預測期內將以 5.9% 的複合年成長率成長，到 2034 年達到 2,625 億美元。

醫藥精細化學品是用於製藥生產的複雜、高純度化學品，可用作中間體、活性成分、組件和特殊試劑。這些化合物需要先進的合成技術和嚴格的品管，才能符合人類治療用途的監管標準。該市場既服務於開發新藥的創新製藥公司，也服務於生產現有產品的學名藥生產商。全球醫療保健需求的成長、人口老化以及特種藥物研發管線的擴展，正在從根本上重塑這些關鍵化學成分的生產環境。

慢性病盛行率不斷上升和人口老化。

在全球範圍內，糖尿病、心血管疾病、癌症和呼吸系統疾病等慢性病的日益增多，直接推動了製藥業對精細化學品的需求。北美、歐洲以及亞太地區人口老化加劇，導致長期用藥需求不斷成長，從而對活性藥物成分（API）和中間體產生了可預測的長期需求。世界衛生組織（WHO）的數據顯示，全球約71%的死亡是由慢性病造成的，這推動了治療性化合物的持續創新。這種持續的醫療保健需求確保了能夠為現有和新藥研發提供高品質、符合監管要求的原料的精細化學品生產商的穩定成長。

嚴格的監管合規性和品質要求

複雜的醫藥精細化學品法律規範為生產商的市場准入和業務擴張帶來了巨大障礙。美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 和各國衛生部門等監管機構實施嚴格的現行藥品生產品質管理規範 (cGMP) 標準，要求提供詳盡的文件、驗證和持續的品質監控。違反監管規定可能導致警告信、進口禁令或工廠停產，帶來巨大的財務和聲譽風險。新化學合成路線的核准流程通常需要數年時間，並且需要在分析和穩定性測試方面投入大量資金。這些監管障礙對小規模生產商尤其不利，導致市場佔有率集中在擁有完善合規體系的大型成熟企業手中。

連續製造製程的廣泛應用

製藥公司正日益從間歇式生產轉向連續式生產，這為精細化學品供應商創造了新的機會。與傳統的間歇式生產相比，連續式生產製程效率更高、溶劑消耗更少、產品品質更穩定。能夠調整合成平台並為連續式生產流程提供原料的精細化學品供應商，可透過長期供應合約獲得競爭優勢。這種生產方式的改變也使得從臨床劑量到商業劑量的規模化生產速度更快，從而縮短了藥物研發週期。那些率先採用與連續式生產相容的精細化學品生產技術的企業，正逐漸成為追求現代化生產策略的創新製藥公司的首選合作夥伴。

供應鏈脆弱性與地緣政治緊張局勢

全球化精細的化學品供應鏈極易受到貿易爭端、關稅和地緣政治衝突造成的衝擊，進而威脅市場的穩定運作。關鍵原料生產集中在特定地區，尤其是亞洲，造成了依賴性風險，而出口限制和物流瓶頸則加劇了這種風險。近期與疫情相關的衝擊暴露了即時（JIT）庫存模式的重大缺陷，促使製藥公司重新評估籌資策略。貿易戰和製裁可能突然限制關鍵中間體的獲取，迫使企業在最後一刻更換供應商並重新獲得監管部門的批准，造成高昂的成本。這些不確定性活性化了關於生產回流的討論，同時也造成了市場波動，並對整個產業的長期投資計畫構成挑戰。

新型冠狀病毒（COVID-19）的影響：

新冠疫情引發了對醫藥精細化學品的空前需求，尤其是用於抗病毒藥物、疫苗和輔助治療藥物的精細化學品。疫情初期，封鎖措施迫使中國和印度的生產設施停工，造成關鍵中間體全球短缺，迫使製藥公司實現關鍵原料來源多元化。然而，對新冠治療藥物的迫切需求加速了法規核准，並促進了先前相互競爭的生產網路之間的合作。疫苗的研發和生產需要大量特殊精細化學品，包括脂質奈米顆粒和佐劑，消耗了相當一部分生產能力。疫情促使製藥公司對庫存策略進行永久性重新評估，如今許多製藥公司都維持著規模大規模的關鍵精細化學品策略儲備。

在預測期內，活性藥物成分（API）細分市場預計將佔據最大的市場佔有率。

預計在預測期內，活性藥物成分（API）細分市場將佔據最大的市場佔有率。這反映了這些化合物在發揮治療作用方面所扮演的關鍵角色。 API是任何藥物的生物活性成分，在所有精細化學品類別中，其品質標準和合成能力要求最為嚴格。不斷擴大的學名藥市場，以及用於特殊療法的複雜新型分子實體的推出，持續推動強勁的需求。製藥公司擴大將API的生產外包給專業的精細化學品製造商，從內部生產轉向夥伴關係模式。這種外包趨勢，加上API是所有成品藥的必要成分，預計將確保API在整個預測期內保持市場主導地位。

在預測期內，生物基精細化學品產業預計將呈現最高的複合年成長率。

在預測期內，生物基精細化學品產業預計將呈現最高的成長率，這主要得益於製藥業對永續生產實踐的推動以及為減少環境影響所做的努力。這些化學物質源自可再生生物來源資源，例如植物生質能、微生物發酵和農業廢棄物，而非石油基原料。領先的製藥公司已設定了雄心勃勃的碳排放目標，並優先選擇能夠透過生物基取代傳統合成路線來降低環境影響的供應商。對溶劑使用和廢棄物產生的監管壓力進一步加速了這些替代方法的應用。此外，對於某些複雜的掌性分子，生物催化生產比傳統的化學合成更有效率，兼具經濟和環境優勢，也推動了市場的快速擴張。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的製藥行業、強勁的研發投入以及有利於成熟供應商的嚴格品質標準。美國是全球最大的藥品市場，學名藥消費廣泛，專科藥品領域持續創新，需要高純度精細化學品。受疫情影響，製藥公司紛紛將生產外包至北美，為該地區的精細化學品生產商帶來了利好。此外，有利的專利保護和強力的智慧財產權執法也為合約研發生產機構（CDMO）創造了穩定的環境。綜合這些因素，預計北美將繼續保持其市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。這主要得益於印度和中國已確立其作為全球醫藥精細化學品製造地。低廉的生產成本、熟練的化學工程人才以及不斷提升的監管合規能力，使這些國家成為創新藥和學名藥企業理想的採購目的地。政府主導的各項舉措，例如中國的「中國製造2025」和印度的醫藥出口促進措施，都在積極推動精細化學品產能的擴張。該地區國內醫藥消費的成長，得益於收入的提高和醫療保健服務的改善，也進一步刺激了需求。隨著全球製藥公司在亞洲實現供應鏈多元化，該地區正崛起為醫藥精細化學品市場成長最快的地區。

免費客製化服務：

所有購買此報告的客戶均可從以下免費自訂選項中選擇一項：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域細分
- 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第10章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第11章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第12章：公司簡介

BASF SE
Lonza Group AG
Siegfried Holding AG
Cambrex Corporation
Piramal Pharma Limited
Thermo Fisher Scientific Inc.
Dr. Reddy's Laboratories Limited
Aurobindo Pharma Limited
Divi's Laboratories Limited
Jubilant Pharmova Limited
Teva Pharmaceutical Industries Limited
Merck KGaA
Solara Active Pharma Sciences Limited
Hikal Limited
Laurus Labs Limited

簡介目錄圖表

Product Code: SMRC37138

According to Stratistics MRC, the Global Pharmaceutical Fine Chemicals Market is accounted for $165.9 billion in 2026 and is expected to reach $262.5 billion by 2034 growing at a CAGR of 5.9% during the forecast period. Pharmaceutical fine chemicals are complex, high-purity chemical substances used as intermediates, active ingredients, building blocks, and specialty reagents in drug manufacturing. These compounds require sophisticated synthesis techniques and stringent quality control to meet regulatory standards for human therapeutic use. The market serves both innovative pharmaceutical companies developing novel drugs and generic manufacturers producing established medications. Growing global healthcare demand, an aging population, and the expanding pipeline of specialty drugs are fundamentally reshaping the production landscape for these critical chemical components.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases and aging population

The global burden of chronic conditions such as diabetes, cardiovascular disorders, cancer, and respiratory diseases continues to rise, directly fueling demand for pharmaceutical fine chemicals used in drug production. An aging demographic across North America, Europe, and increasingly in Asia Pacific requires sustained medication regimens, creating predictable long-term demand for active pharmaceutical ingredients (APIs) and intermediates. The World Health Organization reports that chronic diseases account for approximately 71% of all deaths globally, driving continuous innovation in therapeutic compounds. This persistent healthcare demand ensures stable growth for fine chemical manufacturers capable of producing high-quality, compliant ingredients for both existing and emerging drug pipelines.

Restraint:

Stringent regulatory compliance and quality requirements

Manufacturers face substantial barriers to market entry and operational expansion due to complex regulatory frameworks governing pharmaceutical fine chemicals. Agencies including the FDA, EMA, and national health authorities impose rigorous current Good Manufacturing Practice (cGMP) standards, requiring extensive documentation, validation, and continuous quality monitoring. Non-compliance can result in warning letters, import bans, or facility shutdowns, creating significant financial and reputational risks. The approval process for new chemical synthesis routes typically spans several years and requires substantial investment in analytical testing and stability studies. These regulatory hurdles particularly disadvantage smaller producers, consolidating market share among established players with dedicated compliance infrastructure.

Opportunity:

Growing adoption of continuous manufacturing processes

Pharmaceutical manufacturers are increasingly shifting from batch processing to continuous manufacturing, creating new opportunities for fine chemical suppliers. Continuous processes offer improved efficiency, reduced solvent consumption, and more consistent product quality compared to traditional batch methods. Fine chemical producers capable of adapting their synthesis platforms to deliver raw materials compatible with continuous workflows gain competitive advantages through long-term supply agreements. This manufacturing evolution also enables faster scale-up from clinical to commercial quantities, reducing drug development timelines. Early adopters of continuous-compatible fine chemical production are positioning themselves as preferred partners for innovative pharmaceutical companies pursuing modern manufacturing strategies.

Threat:

Supply chain vulnerabilities and geopolitical tensions

Globalized fine chemical supply chains remain exposed to disruptions from trade disputes, tariffs, and geopolitical conflicts, threatening reliable market operation. The concentration of key raw material production in specific regions, particularly Asia, creates dependency risks amplified by export restrictions or logistical bottlenecks. Recent pandemic-related disruptions exposed critical vulnerabilities in just-in-time inventory models, prompting pharmaceutical companies to reconsider sourcing strategies. Potential trade wars or sanctions could abruptly restrict access to essential intermediates, forcing costly last-minute supplier changes and regulatory reapprovals. This uncertainty drives reshoring discussions but also creates market volatility that challenges long-term investment planning across the sector.

Covid-19 Impact:

The COVID-19 pandemic triggered unprecedented demand for pharmaceutical fine chemicals, particularly those used in antiviral medications, vaccines, and supportive care drugs. Lockdowns initially disrupted Chinese and Indian production facilities, creating global shortages of key intermediates and forcing pharmaceutical companies to dual-source critical inputs. However, the urgent need for COVID-19 therapeutics accelerated regulatory approvals and fostered collaboration across previously competitive manufacturing networks. Vaccine development and production required massive quantities of specialty fine chemicals, including lipid nanoparticles and adjuvants, absorbing significant manufacturing capacity. The pandemic permanently elevated inventory strategies, with many drugmakers now maintaining larger strategic reserves of essential fine chemicals.

The Active Pharmaceutical Ingredients (APIs) segment is expected to be the largest during the forecast period

The Active Pharmaceutical Ingredients (APIs) segment is expected to account for the largest market share during the forecast period, reflecting the essential role these compounds play in delivering therapeutic effects. APIs represent the biologically active component of any pharmaceutical product, requiring the most rigorous quality standards and sophisticated synthesis capabilities among all fine chemical categories. The expanding generic drug market, combined with the introduction of complex new molecular entities for specialty therapies, continues to drive robust demand. Pharmaceutical companies increasingly outsource API manufacturing to specialized fine chemical producers, shifting from captive production to partnership models. This outsourcing trend, coupled with the non-negotiable necessity of APIs in every finished drug product, ensures market dominance throughout the forecast timeline.

The Bio-Based Fine Chemicals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Bio-Based Fine Chemicals segment is predicted to witness the highest growth rate, driven by the pharmaceutical industry's push toward sustainable manufacturing practices and reduced environmental impact. These chemicals are derived from renewable biological sources including plant biomass, microbial fermentation, and agricultural waste rather than petroleum feedstocks. Major drug manufacturers are establishing ambitious carbon reduction targets, favoring suppliers who can demonstrate lower environmental footprints through bio-based alternatives to traditional synthetic routes. Regulatory pressure on solvent usage and waste generation further accelerates adoption. Additionally, certain complex chiral molecules are more efficiently produced through biocatalysis than traditional chemical synthesis, offering both economic and environmental advantages that propel rapid market expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by a mature pharmaceutical industry, robust R&D investment, and strict quality standards favoring established suppliers. The United States represents the world's largest pharmaceutical market, with extensive generic drug consumption and continuous innovation in specialty medicines requiring high-purity fine chemicals. Nearshoring trends emerging from pandemic disruptions are prompting pharmaceutical companies to secure North American supply sources, benefiting regional fine chemical manufacturers. Additionally, favorable patent protections and strong intellectual property enforcement create secure environments for contract development and manufacturing organizations. These factors collectively ensure North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, led by India and China's established positions as global pharmaceutical fine chemical manufacturing hubs. Lower production costs, skilled chemical engineering talent, and expanding regulatory compliance capabilities make these countries preferred sourcing destinations for both innovative and generic drug companies. Government initiatives, including China's "Made in China 2025" and India's pharmaceutical export promotion schemes, actively support fine chemical capacity expansion. The region's growing domestic pharmaceutical consumption, driven by rising incomes and healthcare access improvements, creates additional demand. As global pharmaceutical companies continue diversifying supply chains within Asia, the region emerges as the fastest-growing market for pharmaceutical fine chemicals.

Key players in the market

Some of the key players in Pharmaceutical Fine Chemicals Market include BASF SE, Lonza Group AG, Siegfried Holding AG, Cambrex Corporation, Piramal Pharma Limited, Thermo Fisher Scientific Inc., Dr. Reddy's Laboratories Limited, Aurobindo Pharma Limited, Divi's Laboratories Limited, Jubilant Pharmova Limited, Teva Pharmaceutical Industries Limited, Merck KGaA, Solara Active Pharma Sciences Limited, Hikal Limited and Laurus Labs Limited.

Key Developments:

In March 2026, Lonza completed its structural evolution into a pure-play CDMO by signing a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an upfront consideration of CHF 1.7 billion.

In March 2026, BASF Pharma Solutions announced a global price increase of up to 20% for pharmaceutical excipients and selected active pharmaceutical ingredients (APIs), designed to offset persistent spikes in energy and raw material costs while securing long-term product availability.

In January 2026, Siegfried officially entered into a binding agreement to buy high-quality small-molecule drug substance capacity in the United States, positioning its Pennsville and Wilmington infrastructure to scale controlled substance operations.

Product Types Covered:

Intermediates
Active Pharmaceutical Ingredients
Building Blocks
Reagents
Solvents
Protecting Agents
Catalysts
Chiral Chemicals
Other Fine Chemicals

Synthesis Types Covered:

Synthetic Fine Chemicals
Bio-Based Fine Chemicals
Fermentation-Derived Chemicals
Semi-Synthetic Chemicals

Applications Covered:

API Manufacturing
Drug Discovery
Formulation Development
Clinical Research
Generic Drug Production
Branded Drug Production

End Users Covered:

Pharmaceutical Companies
Biotechnology Companies
Contract Development and Manufacturing Organizations
Research Institutes
Academic and Government Laboratories

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Pharmaceutical Fine Chemicals Market, By Product Type

5.1 Intermediates
5.2 Active Pharmaceutical Ingredients
5.3 Building Blocks
5.4 Reagents
5.5 Solvents
5.6 Protecting Agents
5.7 Catalysts
5.8 Chiral Chemicals
5.9 Other Fine Chemicals

6 Global Pharmaceutical Fine Chemicals Market, By Synthesis Type

6.1 Synthetic Fine Chemicals
6.2 Bio-Based Fine Chemicals
6.3 Fermentation-Derived Chemicals
6.4 Semi-Synthetic Chemicals

7 Global Pharmaceutical Fine Chemicals Market, By Application

7.1 API Manufacturing
7.2 Drug Discovery
7.3 Formulation Development
7.4 Clinical Research
7.5 Generic Drug Production
7.6 Branded Drug Production

8 Global Pharmaceutical Fine Chemicals Market, By End User

8.1 Pharmaceutical Companies
8.2 Biotechnology Companies
8.3 Contract Development and Manufacturing Organizations
8.4 Research Institutes
8.5 Academic and Government Laboratories

9 Global Pharmaceutical Fine Chemicals Market, By Geography

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 United Kingdom
- 9.2.2 Germany
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Netherlands
- 9.2.7 Belgium
- 9.2.8 Sweden
- 9.2.9 Switzerland
- 9.2.10 Poland
- 9.2.11 Rest of Europe
9.3 Asia Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 South Korea
- 9.3.5 Australia
- 9.3.6 Indonesia
- 9.3.7 Thailand
- 9.3.8 Malaysia
- 9.3.9 Singapore
- 9.3.10 Vietnam
- 9.3.11 Rest of Asia Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Colombia
- 9.4.4 Chile
- 9.4.5 Peru
- 9.4.6 Rest of South America
9.5 Rest of the World (RoW)
- 9.5.1 Middle East
  - 9.5.1.1 Saudi Arabia
  - 9.5.1.2 United Arab Emirates
  - 9.5.1.3 Qatar
  - 9.5.1.4 Israel
  - 9.5.1.5 Rest of Middle East
- 9.5.2 Africa
  - 9.5.2.1 South Africa
  - 9.5.2.2 Egypt
  - 9.5.2.3 Morocco
  - 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives

12 Company Profiles

12.1 BASF SE
12.2 Lonza Group AG
12.3 Siegfried Holding AG
12.4 Cambrex Corporation
12.5 Piramal Pharma Limited
12.6 Thermo Fisher Scientific Inc.
12.7 Dr. Reddy's Laboratories Limited
12.8 Aurobindo Pharma Limited
12.9 Divi's Laboratories Limited
12.10 Jubilant Pharmova Limited
12.11 Teva Pharmaceutical Industries Limited
12.12 Merck KGaA
12.13 Solara Active Pharma Sciences Limited
12.14 Hikal Limited
12.15 Laurus Labs Limited

簡介目錄圖表

List of Tables

Table 1 Global Pharmaceutical Fine Chemicals Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Pharmaceutical Fine Chemicals Market Outlook, By Product Type (2023-2034) ($MN)
Table 3 Global Pharmaceutical Fine Chemicals Market Outlook, By Intermediates (2023-2034) ($MN)
Table 4 Global Pharmaceutical Fine Chemicals Market Outlook, By Active Pharmaceutical Ingredients (2023-2034) ($MN)
Table 5 Global Pharmaceutical Fine Chemicals Market Outlook, By Building Blocks (2023-2034) ($MN)
Table 6 Global Pharmaceutical Fine Chemicals Market Outlook, By Reagents (2023-2034) ($MN)
Table 7 Global Pharmaceutical Fine Chemicals Market Outlook, By Solvents (2023-2034) ($MN)
Table 8 Global Pharmaceutical Fine Chemicals Market Outlook, By Protecting Agents (2023-2034) ($MN)
Table 9 Global Pharmaceutical Fine Chemicals Market Outlook, By Catalysts (2023-2034) ($MN)
Table 10 Global Pharmaceutical Fine Chemicals Market Outlook, By Chiral Chemicals (2023-2034) ($MN)
Table 11 Global Pharmaceutical Fine Chemicals Market Outlook, By Other Fine Chemicals (2023-2034) ($MN)
Table 12 Global Pharmaceutical Fine Chemicals Market Outlook, By Synthesis Type (2023-2034) ($MN)
Table 13 Global Pharmaceutical Fine Chemicals Market Outlook, By Synthetic Fine Chemicals (2023-2034) ($MN)
Table 14 Global Pharmaceutical Fine Chemicals Market Outlook, By Bio-Based Fine Chemicals (2023-2034) ($MN)
Table 15 Global Pharmaceutical Fine Chemicals Market Outlook, By Fermentation-Derived Chemicals (2023-2034) ($MN)
Table 16 Global Pharmaceutical Fine Chemicals Market Outlook, By Semi-Synthetic Chemicals (2023-2034) ($MN)
Table 17 Global Pharmaceutical Fine Chemicals Market Outlook, By Application (2023-2034) ($MN)
Table 18 Global Pharmaceutical Fine Chemicals Market Outlook, By API Manufacturing (2023-2034) ($MN)
Table 19 Global Pharmaceutical Fine Chemicals Market Outlook, By Drug Discovery (2023-2034) ($MN)
Table 20 Global Pharmaceutical Fine Chemicals Market Outlook, By Formulation Development (2023-2034) ($MN)
Table 21 Global Pharmaceutical Fine Chemicals Market Outlook, By Clinical Research (2023-2034) ($MN)
Table 22 Global Pharmaceutical Fine Chemicals Market Outlook, By Generic Drug Production (2023-2034) ($MN)
Table 23 Global Pharmaceutical Fine Chemicals Market Outlook, By Branded Drug Production (2023-2034) ($MN)
Table 24 Global Pharmaceutical Fine Chemicals Market Outlook, By End User (2023-2034) ($MN)
Table 25 Global Pharmaceutical Fine Chemicals Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
Table 26 Global Pharmaceutical Fine Chemicals Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
Table 27 Global Pharmaceutical Fine Chemicals Market Outlook, By Contract Development and Manufacturing Organizations (2023-2034) ($MN)
Table 28 Global Pharmaceutical Fine Chemicals Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 29 Global Pharmaceutical Fine Chemicals Market Outlook, By Academic and Government Laboratories (2023-2034) ($MN)